Literature DB >> 19786834

Methylation analysis of the imprinted DLK1-GTL2 domain supports the random parental origin of the IGH-involving del(14q) in B-cell malignancies.

Beata Katrincsakova1, Haruko Takeda, Helena Urbankova, Lucienne Michaux, Marie Jarosova, Peter Vandenberghe, Michel Georges, Carole Charlier, Iwona Wlodarska.   

Abstract

Leukemias/lymphomas with IGH-involving del(14q)(1) commonly lose the DLK1-GTL2 imprinted domain that comprises several paternally and maternally expressed genes, including a cluster of microRNAs. Given that deletion of this region could lead to inactivation of a monoallelically expressed tumor suppressor gene, our study aimed at determination of the parental origin of del(14q/IGH). The designed allele-specific methylation study of the DLK1/GTL2 intergenic differentially methylated region allowed us to determine the parental origin of del(14q/IGH) in 9/20 analyzed cases. In six cases del(14q/IGH) was of the paternal origin and in three cases of the maternal origin. These findings argue against the concept that a TSG/anti-oncomir located in the imprinted region is systematically inactivated by a targeted deletion of its functional allele.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19786834     DOI: 10.4161/epi.4.7.9924

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  2 in total

1.  Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements.

Authors:  Francesco Albano; Luisa Anelli; Antonella Zagaria; Nicoletta Coccaro; Paola Casieri; Antonella Russo Rossi; Laura Vicari; Vincenzo Liso; Mariano Rocchi; Giorgina Specchia
Journal:  Mol Cancer       Date:  2010-05-25       Impact factor: 27.401

2.  MiR-148a regulates MEG3 in gastric cancer by targeting DNA methyltransferase 1.

Authors:  Jiang Yan; Xiaoqiang Guo; Jiazeng Xia; Tin Shan; Chen Gu; Zheng Liang; Wei Zhao; Shimao Jin
Journal:  Med Oncol       Date:  2014-02-11       Impact factor: 3.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.